Healthcare -
Biotechnology - NASDAQ - NL
$ 18.92
-6.13 %
$ 2.12 B
Market Cap
-7.42
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
NewAmsterdam Pharma Company N.V.
| Net Income | -242 M |
| Depreciation & Amortization | 113 K |
| Capital Expenditures | -672 K |
| Stock-Based Compensation | 33.6 M |
| Change in Working Capital | -32.7 M |
| Others | 62.2 M |
| Free Cash Flow | -159 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (241.6) | (176.9) | (78.1) | (28.6) | (5.7) |
| Depreciation & Amortization | 0.1 | 49 K | 72 K | 14 K | 1 K |
| Deferred Income Tax | 0 | 0 | 0 | (1.4) | 0 |
| Stock Based Compensation | 33.6 | 24.6 | 4.1 | 1.2 | 0 |
| Other Operating Activities | 82.0 | 5.2 | 70.6 | 7 K | 0.3 |
| Change in Working Capital | (32.7) | 5.9 | 11.5 | 3.8 | (0.5) |
| Cash From Operations | (158.6) | (141.2) | 8.0 | (25.2) | (6.0) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (0.7) | 24 K | 13 K | 20 K | 13 K |
| Other Items | (62.2) | 0 | 0.7 | 0 | 0 |
| Cash From Investing Activities | (62.8) | 24 K | 0.7 | 20 K | 13 K |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0.7 | 0 | 13.9 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 14.0 | 8.9 | (5.8) | (15.7) | (2.6) |
| Cash From Financing Activities | 659.5 | 8.9 | 375.2 | 69.0 | 11.3 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 431.3 | (127.3) | 385.4 | 45.2 | 5.4 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (159.2) | (141.2) | 8.0 | (25.2) | (6.0) |